Overview

Exploratory Study of IFX-1 in Subjects With Pyoderma Gangrenosum

Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether IFX-1 is safe and effective in the treatment of pyoderma gangrenosum.
Phase:
Phase 2
Details
Lead Sponsor:
InflaRx GmbH
Collaborator:
Innovaderm Research Inc.
Treatments:
Vilobelimab